Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts.
Chouaid C, Thomas M, Debieuvre D, Durand-Zaleski I, Zacharias S, Bosquet L, Groth A, Fleitz A, Calleja A, Patel S, Lacoin L, Daumont MJ, Penrod JR, Carroll R, Waldenberger D, Cotté FE, Audigier-Valette C, Griesinger F. Chouaid C, et al. Among authors: penrod jr. Cancers (Basel). 2022 Dec 13;14(24):6148. doi: 10.3390/cancers14246148. Cancers (Basel). 2022. PMID: 36551632 Free PMC article.
Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018.
Wolf A, Stratmann JA, Shaid S, Niklas N, Calleja A, Ubhi H, Munro R, Waldenberger D, Carroll R, Daumont MJ, Penrod JR, Lacoin L, Rohde G. Wolf A, et al. Among authors: penrod jr. BMC Pulm Med. 2023 Jan 13;23(1):16. doi: 10.1186/s12890-022-02288-1. BMC Pulm Med. 2023. PMID: 36639770 Free PMC article.
Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study.
Provencio M, Carcereny E, López Castro R, Calvo V, Rodríguez Abreu D, Cobo M, Ortega AL, Bernabé R, Guirado M, Massutí B, Del Barco-Morillo E, Bosch-Barrera J, Camps C, Carroll R, Rault C, Chaib C, Penrod J, Vo L, Ralphs E, Daumont MJ. Provencio M, et al. Transl Lung Cancer Res. 2023 Oct 31;12(10):2113-2128. doi: 10.21037/tlcr-23-176. Epub 2023 Oct 27. Transl Lung Cancer Res. 2023. PMID: 38025806 Free PMC article.
Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer.
Reck M, De T, Paz-Ares L, Edmondson-Jones M, Yuan Y, Yates G, Zoffoli R, Chaudhary MA, Lee A, Varol N, Penrod JR. Reck M, et al. Among authors: penrod jr. Clin Lung Cancer. 2024 Nov;25(7):e362-e368. doi: 10.1016/j.cllc.2024.06.005. Epub 2024 Jun 29. Clin Lung Cancer. 2024. PMID: 39097467 Free article. Clinical Trial.
Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP, Ciuleanu TE, Schenker M, Cobo M, Bordenave S, Juan-Vidal O, Menezes J, Reinmuth N, Richardet E, Cheng Y, Mizutani H, Felip E, Zurawski B, Alexandru A, Paz-Ares L, Lu S, John T, Zhang X, Mahmood J, Hu N, De T, Santi I, Penrod JR, Yuan Y, Lee A, Reck M. Carbone DP, et al. Among authors: penrod jr. J Immunother Cancer. 2024 Feb 12;12(2):e008189. doi: 10.1136/jitc-2023-008189. J Immunother Cancer. 2024. PMID: 38346853 Free PMC article. Clinical Trial.
96 results